{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "34103557", "DateCompleted": {"Year": "2021", "Month": "11", "Day": "15"}, "DateRevised": {"Year": "2023", "Month": "11", "Day": "01"}, "Article": {"ArticleDate": [{"Year": "2021", "Month": "06", "Day": "08"}], "Language": ["eng"], "ELocationID": ["12040", "10.1038/s41598-021-90545-4"], "Journal": {"ISSN": "2045-2322", "JournalIssue": {"Volume": "11", "Issue": "1", "PubDate": {"Year": "2021", "Month": "Jun", "Day": "08"}}, "Title": "Scientific reports", "ISOAbbreviation": "Sci Rep"}, "ArticleTitle": "Peganum harmala enhanced GLP-1 and restored insulin signaling to alleviate AlCl<sub>3</sub>-induced Alzheimer-like pathology model.", "Pagination": {"StartPage": "12040", "MedlinePgn": "12040"}, "Abstract": {"AbstractText": ["Peganum harmala (P. harmala) is a folk medicinal herb used in the Sinai Peninsula (Egypt) as a remedy for central disorders. The main constituents, harmine and harmaline, have displayed therapeutic efficacy against Alzheimer's disease (AD); however, the P. harmala potential on sensitizing central insulin to combat AD remains to be clarified. An AD-like rat model was induced by aluminum chloride (AlCl<sub>3</sub>; 50 mg/kg/day for six consecutive weeks; i.p), whereas a methanolic standardized P. harmala seed extract (187.5 mg/kg; p.o) was given to AD rats starting 2 weeks post AlCl<sub>3</sub> exposure. Two additional groups of rats were administered either the vehicle to serve as the normal control or the vehicle\u2009+\u2009P. harmala seed extract to serve as the P. harmala control group. P. harmala enhanced cognition appraised by Y-maze and Morris water maze tests and improved histopathological structures altered by AlCl<sub>3</sub>. Additionally, it heightened the hippocampal contents of glucagon-like peptide (GLP)-1 and insulin, but abated insulin receptor substrate-1 phosphorylation at serine 307 (pS307-IRS-1). Besides, P. harmala increased phosphorylated Akt at serine 473 (pS473-Akt) and glucose transporter type (GLUT)4. The extract also curtailed the hippocampal content of beta amyloid (A\u03b2)42, glycogen synthase (GSK)-3\u03b2 and phosphorylated tau. It also enhanced Nrf2, while reduced lipid peroxides and replenished glutathione. In conclusion, combating insulin resistance by P. harmala is a novel machinery in attenuating the insidious progression of AD by enhancing both insulin and GLP-1 trajectories in the hippocampus favoring GLUT4 production."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Cairo, Egypt."}], "LastName": "Saleh", "ForeName": "Rofida A", "Initials": "RA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Faculty of Biotechnology, October University for Modern Sciences and Arts (MSA), Giza, Egypt."}], "LastName": "Eissa", "ForeName": "Tarek F", "Initials": "TF"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Cairo, Egypt. dalaal.abdallah@pharma.cu.edu.eg."}], "LastName": "Abdallah", "ForeName": "Dalaal M", "Initials": "DM"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Cairo, Egypt."}, {"Identifier": [], "Affiliation": "Department of Pharmacology and Toxicology, School of Pharmacy, Newgiza University, Cairo, Egypt."}], "LastName": "Saad", "ForeName": "Muhammed A", "Initials": "MA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Cairo, Egypt."}, {"Identifier": [], "Affiliation": "Department of Pharmacology, Toxicology & Biochemistry, Faculty of Pharmaceutical Sciences and Pharmaceutical Industries, Future University in Egypt, Cairo, Egypt."}], "LastName": "El-Abhar", "ForeName": "Hanan S", "Initials": "HS"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "Sci Rep", "NlmUniqueID": "101563288", "ISSNLinking": "2045-2322"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Amyloid beta-Peptides"}, {"RegistryNumber": "0", "NameOfSubstance": "Glucagon-Like Peptide-1 Receptor"}, {"RegistryNumber": "0", "NameOfSubstance": "Insulin"}, {"RegistryNumber": "3CYT62D3GA", "NameOfSubstance": "Aluminum Chloride"}, {"RegistryNumber": "CN58I4TOET", "NameOfSubstance": "Harmaline"}, {"RegistryNumber": "EC 2.7.11.1", "NameOfSubstance": "Glycogen Synthase Kinase 3 beta"}, {"RegistryNumber": "EC 2.7.11.1", "NameOfSubstance": "Gsk3b protein, rat"}], "MeshHeadingList": [{"QualifierName": ["chemistry"], "DescriptorName": "Aluminum Chloride"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Alzheimer Disease"}, {"QualifierName": ["metabolism"], "DescriptorName": "Amyloid beta-Peptides"}, {"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": [], "DescriptorName": "Behavior, Animal"}, {"QualifierName": [], "DescriptorName": "Cognition"}, {"QualifierName": [], "DescriptorName": "Disease Models, Animal"}, {"QualifierName": [], "DescriptorName": "Disease Progression"}, {"QualifierName": ["metabolism"], "DescriptorName": "Glucagon-Like Peptide-1 Receptor"}, {"QualifierName": ["metabolism"], "DescriptorName": "Glycogen Synthase Kinase 3 beta"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Harmaline"}, {"QualifierName": ["metabolism"], "DescriptorName": "Hippocampus"}, {"QualifierName": ["metabolism"], "DescriptorName": "Insulin"}, {"QualifierName": [], "DescriptorName": "Insulin Resistance"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": [], "DescriptorName": "Maze Learning"}, {"QualifierName": [], "DescriptorName": "Neurosciences"}, {"QualifierName": ["chemistry", "metabolism"], "DescriptorName": "Peganum"}, {"QualifierName": [], "DescriptorName": "Phosphorylation"}, {"QualifierName": ["metabolism"], "DescriptorName": "Plants, Medicinal"}, {"QualifierName": [], "DescriptorName": "Rats"}, {"QualifierName": [], "DescriptorName": "Rats, Wistar"}, {"QualifierName": [], "DescriptorName": "Signal Transduction"}], "CoiStatement": "The authors declare no competing interests."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Bl\u00e1zquez E, Vel\u00e1zquez E, Hurtado-carneiro V, Ruiz-Albusac JM. Insulin in the brain: Its pathophysiological implications for states related with central insulin resistance, type 2 diabetes and alzheimer \u2019 s disease. Front. Endocrinol. 2014;5:1\u201321. doi: 10.3389/fendo.2014.00161.", "ArticleIdList": ["10.3389/fendo.2014.00161", "PMC4191295", "25346723"]}, {"Citation": "Kandimalla R, Thirumala V, Reddy PH. Is Alzheimer\u2019s disease a type 3 diabetes? A critical appraisal. Biochim. Biophys. Acta. Mol. Basis Dis. 2017;1863:1078\u20131089. doi: 10.1016/j.bbadis.2016.08.018.", "ArticleIdList": ["10.1016/j.bbadis.2016.08.018", "PMC5344773", "27567931"]}, {"Citation": "Kuwabara T, et al. Insulin biosynthesis in neuronal progenitors derived from adult hippocampus and the olfactory bulb. EMBO Mol. Med. 2011;3:742\u2013754. doi: 10.1002/emmm.201100177.", "ArticleIdList": ["10.1002/emmm.201100177", "PMC3377118", "21984534"]}, {"Citation": "Ferrario CR, Reagan LP. Insulin-mediated synaptic plasticity in the CNS: Anatomical, functional and temporal contexts. Neuropharmacology. 2018;136:182\u2013191. doi: 10.1016/j.neuropharm.2017.12.001.", "ArticleIdList": ["10.1016/j.neuropharm.2017.12.001", "PMC5988909", "29217283"]}, {"Citation": "Satoh F, et al. Characterization of human and rat glucagon-like peptide-1 receptors in the neurointermediate lobe: Lack of coupling to either stimulation or inhibition of adenylyl cyclase. Endocrinology. 2000;141:1301\u20131309. doi: 10.1210/endo.141.4.7420.", "ArticleIdList": ["10.1210/endo.141.4.7420", "10746632"]}, {"Citation": "Li Y, et al. GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc. Natl. Acad. Sci. USA. 2009;106:1285\u20131290. doi: 10.1073/pnas.0806720106.", "ArticleIdList": ["10.1073/pnas.0806720106", "PMC2633544", "19164583"]}, {"Citation": "M\u00fcller TD, et al. Glucagon-like peptide 1 (GLP-1) Mol. Metab. 2019;30:72\u2013130. doi: 10.1016/j.molmet.2019.09.010.", "ArticleIdList": ["10.1016/j.molmet.2019.09.010", "PMC6812410", "31767182"]}, {"Citation": "Chang C, Lin T, Ho H, Kuo C, Li H. GLP-1 analogue liraglutide attenuates mutant huntingtin-induced neurotoxicity by restoration of neuronal insulin signaling. Int. J. Mol. Sci. 2018;19:2505. doi: 10.3390/ijms19092505.", "ArticleIdList": ["10.3390/ijms19092505", "PMC6164932", "30149534"]}, {"Citation": "Biessels GJ, Reagan LP. Hippocampal insulin resistance and cognitive dysfunction. Nat. Rev. Neurosci. 2015;16:660\u2013671. doi: 10.1038/nrn4019.", "ArticleIdList": ["10.1038/nrn4019", "26462756"]}, {"Citation": "De la Monte SM, Wands JR. Alzheimer\u2019s disease is type 3 diabetes: Evidence reviewed. J. Diabetes Sci. Technol. 2008;2:1101\u20131113. doi: 10.1177/193229680800200619.", "ArticleIdList": ["10.1177/193229680800200619", "PMC2769828", "19885299"]}, {"Citation": "de la Monte SM. Type 3 diabetes is sporadic Alzheimer\u05f3s disease: Mini-review. Eur. Neuropsychopharmacol. 2014;24:1954\u20131960. doi: 10.1016/j.euroneuro.2014.06.008.", "ArticleIdList": ["10.1016/j.euroneuro.2014.06.008", "PMC4444430", "25088942"]}, {"Citation": "Steen E, et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer\u2019s disease: Is this type 3 diabetes ? J. Alzheimers Dis. 2005;7:63\u201380. doi: 10.3233/JAD-2005-7107.", "ArticleIdList": ["10.3233/JAD-2005-7107", "15750215"]}, {"Citation": "Han X, et al. Insulin attenuates beta-amyloid-associated Insulin/Akt/EAAT signaling perturbations in human astrocytes. Cell. Mol. Neurobiol. 2016;36:851\u2013864. doi: 10.1007/s10571-015-0268-5.", "ArticleIdList": ["10.1007/s10571-015-0268-5", "PMC5502723", "26358886"]}, {"Citation": "Lee JH, Jahrling JB, Denner L, Dineley KT. Targeting insulin for Alzheimer\u2019s disease: Mechanisms, status and potential directions. J. Alzheimers Dis. 2018;64:427\u2013453. doi: 10.3233/JAD-179923.", "ArticleIdList": ["10.3233/JAD-179923", "29710715"]}, {"Citation": "Mullins RJ, Diehl TC, Chia CW, Kapogiannis D. Insulin resistance as a link between amyloid-beta and tau pathologies in Alzheimer\u2019s disease. Front. Aging Neurosci. 2017;9:1\u201316. doi: 10.3389/fnagi.2017.00118.", "ArticleIdList": ["10.3389/fnagi.2017.00118", "PMC5413582", "28515688"]}, {"Citation": "Butterfield DA, Di Domenico F, Barone E. Elevated risk of type 2 diabetes for development of Alzheimer disease: A key role for oxidative stress in brain. Biochim. Biophys. Acta. 2014;1842:1693\u20131706. doi: 10.1016/j.bbadis.2014.06.010.", "ArticleIdList": ["10.1016/j.bbadis.2014.06.010", "PMC4125611", "24949886"]}, {"Citation": "Butterfield DA, Swomley AM, Sultana R. Amyloid \u03b2-peptide (1\u201342)-induced oxidative stress in Alzheimer disease: Importance in disease pathogenesis and progression. Antioxid. Redox Signal. 2013;19:823\u2013835. doi: 10.1089/ars.2012.5027.", "ArticleIdList": ["10.1089/ars.2012.5027", "PMC3749710", "23249141"]}, {"Citation": "Verdile G, et al. Inflammation and oxidative stress: The molecular connectivity between insulin resistance, obesity, and Alzheimer\u2019s disease. Mediat. Inflamm. 2015;2015:105828. doi: 10.1155/2015/105828.", "ArticleIdList": ["10.1155/2015/105828", "PMC4674598", "26693205"]}, {"Citation": "YildirimSimsir I, Soyaltin UE, Cetinkalp S. Glucagon like peptide-1 (GLP-1) likes Alzheimer\u2019s disease. Diabetes Metab. Syndr. 2018;12:469\u2013475. doi: 10.1016/j.dsx.2018.03.002.", "ArticleIdList": ["10.1016/j.dsx.2018.03.002", "29598932"]}, {"Citation": "Cukierman-Yaffe T, et al. Effect of dulaglutide on cognitive impairment in type 2 diabetes: An exploratory analysis of the REWIND trial. Lancet Neurol. 2020;19:582\u2013590. doi: 10.1016/S1474-4422(20)30173-3.", "ArticleIdList": ["10.1016/S1474-4422(20)30173-3", "32562683"]}, {"Citation": "Asgarpana J, Ramezanloo F. Chemistry, pharmacology and medicinal properties of Peganum harmala L. Afr. J. Pharm. Pharmacol. 2012;6:1573\u20131580."}, {"Citation": "Eissa TAF, Palomino OM, Carretero ME, G\u00f3mez-serranillos MP. Ethnopharmacological study of medicinal plants used in the treatment of CNS disorders in Sinai Peninsula, Egypt. J. Ethnopharmacol. 2014;151:317\u2013332. doi: 10.1016/j.jep.2013.10.041.", "ArticleIdList": ["10.1016/j.jep.2013.10.041", "24184194"]}, {"Citation": "Araujo I, et al. Chemical study of Peganum harmala seeds. Afr. J. Biotechnol. 2019;18:462\u2013471. doi: 10.5897/AJB2019.16762.", "ArticleIdList": ["10.5897/AJB2019.16762"]}, {"Citation": "Komeili G, Hashemi M, Bameri-niafar M. Evaluation of antidiabetic and antihyperlipidemic effects of Peganum harmala seeds in diabetic rats. Cholesterol. 2016;2016:1\u20136. doi: 10.1155/2016/7389864.", "ArticleIdList": ["10.1155/2016/7389864", "PMC4848417", "27190643"]}, {"Citation": "Osman NN, Alanbari KH, Al-Shreef HA. Evaluation of the possible antioxidant effects of Peganum harmala and Ginkgo biloba in ameliorating Alzheimer\u2019s disease in rat model. IJPSR. 2018;9:3189\u20133198."}, {"Citation": "Ali SK, et al. In-vitro evaluation of selected Egyptian traditional herbal medicines for treatment of Alzheimer disease. BMC Complement. Altern. Med. 2013;13:1\u201310. doi: 10.1186/1472-6882-13-1.", "ArticleIdList": ["10.1186/1472-6882-13-1", "PMC3701527", "23721591"]}, {"Citation": "Ghaffar S, Afridi SK, Aftab MF, Murtaza M, Syed SA, Begum S. Attenuation of palmitate induced insulin resistance in muscle cells by harmala, clove and river red gum. Pak. J. Pharm. Sci. 2016;29:1795\u20131800.", "ArticleIdList": ["28476704"]}, {"Citation": "Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research. PLOS Biol. 2010;8:e1000412. doi: 10.1371/journal.pbio.1000412.", "ArticleIdList": ["10.1371/journal.pbio.1000412", "PMC2893951", "20613859"]}, {"Citation": "Bazzari FH, Abdallah DM, El-abhar HS. Chenodeoxycholic acid ameliorates AlCl3-induced Alzheimer\u2019s disease neurotoxicity and cognitive deterioration via enhanced insulin signaling in rats. Molecules. 2019;24:1\u201317. doi: 10.3390/molecules24101992.", "ArticleIdList": ["10.3390/molecules24101992", "PMC6571973", "31137621"]}, {"Citation": "Hughes RN. The value of spontaneous alternation behavior (SAB) as a test of retention in pharmacological investigations of memory. Neurosci. Biobehav. Rev. 2004;28:497\u2013505. doi: 10.1016/j.neubiorev.2004.06.006.", "ArticleIdList": ["10.1016/j.neubiorev.2004.06.006", "15465137"]}, {"Citation": "Justin-thenmozhi A, et al. Attenuation of aluminum chloride-induced neuroinflammation and caspase activation through the AKT/GSK-3\u03b2 pathway by hesperidin in wistar rats. Neurotox. Res. 2018;34:463\u2013476. doi: 10.1007/s12640-018-9904-4.", "ArticleIdList": ["10.1007/s12640-018-9904-4", "29687202"]}, {"Citation": "Snow WM, et al. Morris water maze training in mice elevates hippocampal levels of transcription factors nuclear factor (erythroid-derived 2)-like 2 and nuclear factor kappa B p65. Front. Mol. Neurosci. 2015;8:1\u201312. doi: 10.3389/fnmol.2015.00070.", "ArticleIdList": ["10.3389/fnmol.2015.00070", "PMC4649017", "26635523"]}, {"Citation": "Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J. Neurosci. Methods. 1984;11:47\u201360. doi: 10.1016/0165-0270(84)90007-4.", "ArticleIdList": ["10.1016/0165-0270(84)90007-4", "6471907"]}, {"Citation": "Vorhees CV, Williams MT. Morris water maze: Procedures for assessing spatial and related forms of learning and memory. Nat. Protoc. 2006;1:848\u2013858. doi: 10.1038/nprot.2006.116.", "ArticleIdList": ["10.1038/nprot.2006.116", "PMC2895266", "17406317"]}, {"Citation": "Cai H-Y, et al. Lixisenatide reduces amyloid plaques, neurofibrillary tangles and neuroinflammation in an APP/PS1/tau mouse model of Alzheimer\u2019s disease. Biochem. Biophys. Res. Commun. 2018;495:1034\u20131040. doi: 10.1016/j.bbrc.2017.11.114.", "ArticleIdList": ["10.1016/j.bbrc.2017.11.114", "29175324"]}, {"Citation": "Gu LH, et al. A thin-layer chromatography-bioautographic method for detecting dipeptidyl peptidase IV inhibitors in plants. J. Chromatogr. A. 2015;11:116\u2013122. doi: 10.1016/j.chroma.2015.07.123.", "ArticleIdList": ["10.1016/j.chroma.2015.07.123", "26283532"]}, {"Citation": "Kosaraju J, et al. Saxagliptin: A dipeptidyl peptidase-4 inhibitor ameliorates streptozotocin induced Alzheimer\u2019s disease. Neuropharmacology. 2013;72:291\u2013300. doi: 10.1016/j.neuropharm.2013.04.008.", "ArticleIdList": ["10.1016/j.neuropharm.2013.04.008", "23603201"]}, {"Citation": "Chen S, et al. DPP-4 inhibitor improves learning and memory deficits and AD-like neurodegeneration by modulating the GLP-1 signaling. Neuropharmacology. 2019;157:107668. doi: 10.1016/j.neuropharm.2019.107668.", "ArticleIdList": ["10.1016/j.neuropharm.2019.107668", "31199957"]}, {"Citation": "Talbot K. Brain insulin resistance in Alzheimer\u2019s disease and its potential treatment with GLP-1 analogs. Neurodegener. Dis. Manag. 2014;4:31\u201340. doi: 10.2217/nmt.13.73.", "ArticleIdList": ["10.2217/nmt.13.73", "PMC4465775", "24640977"]}, {"Citation": "Naresh G, et al. Glucose uptake stimulatory effect of 4-hydroxypipecolic acid by increased GLUT 4 translocation in skeletal muscle cells. Bioorg. Med. Chem. Lett. 2012;22:5648\u20135651. doi: 10.1016/j.bmcl.2012.06.101.", "ArticleIdList": ["10.1016/j.bmcl.2012.06.101", "22840238"]}, {"Citation": "Talbot K, Wang H-Y. The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer\u2019s disease. Alzheimers Demen. 2014;10:1\u201325. doi: 10.1016/j.jalz.2013.12.007.", "ArticleIdList": ["10.1016/j.jalz.2013.12.007", "PMC4018451", "24529520"]}, {"Citation": "Long-Smith CM, et al. The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-\u03b2 Plaque and glial pathology in a mouse model of Alzheimer\u2019 s disease. Neuromol. Med. 2013;15:102\u2013114. doi: 10.1007/s12017-012-8199-5.", "ArticleIdList": ["10.1007/s12017-012-8199-5", "23011726"]}, {"Citation": "Yarchaon M, Arnold SE. Repurposing diabetes drugs for brain insulin resistance in Alzheimer disease. Diabetes. 2014;63:2253\u20132261. doi: 10.2337/db14-0287.", "ArticleIdList": ["10.2337/db14-0287", "PMC4066335", "24931035"]}, {"Citation": "Gupta NA, et al. Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology. 2010;51:1584\u20131592. doi: 10.1002/hep.23569.", "ArticleIdList": ["10.1002/hep.23569", "PMC2862093", "20225248"]}, {"Citation": "Vyas AK, et al. Exenatide improves glucose homeostasis and prolongs survival in a murine model of dilated cardiomyopathy. PLoS ONE. 2011;6:e17178. doi: 10.1371/journal.pone.0017178.", "ArticleIdList": ["10.1371/journal.pone.0017178", "PMC3040766", "21359201"]}, {"Citation": "Mcnay EC, Pearson-leary J. GluT4: A central player in hippocampal memory and brain insulin resistance. Exp. Neurol. 2020;323:1\u20139. doi: 10.1016/j.expneurol.2019.113076.", "ArticleIdList": ["10.1016/j.expneurol.2019.113076", "PMC6936336", "31614121"]}, {"Citation": "Bae CS, Song J. The role of glucagon-like peptide 1 (GLP1) in type 3 diabetes: GLP-1 controls insulin resistance, neuroinflammation and neurogenesis in the brain. Int. J. Mol. Sci. 2017;18:1\u20137. doi: 10.3390/ijms18112493.", "ArticleIdList": ["10.3390/ijms18112493", "PMC5713459", "29165354"]}, {"Citation": "Aulston BD, Shapansky J, Huang Y, Odero GL, Glazner GW. Secreted amyloid precursor protein alpha activates neuronal insulin receptors and prevents diabetes-induced encephalopathy. Exp. Neurol. 2018;303:29\u201337. doi: 10.1016/j.expneurol.2018.01.013.", "ArticleIdList": ["10.1016/j.expneurol.2018.01.013", "29410317"]}, {"Citation": "Huang C, Wang C, Id CL, Yen A, Li H. Abelmoschus esculentus subfractions attenuate beta amyloid-induced neuron apoptosis by regulating DPP-4 with improving insulin resistance signals. PLoS ONE. 2019;14:1\u201313.", "ArticleIdList": ["PMC6592593", "31237881"]}, {"Citation": "Xie L, et al. Alzheimer\u2019s beta-amyloid peptides compete for insulin binding to the insulin receptor. J. Neurosci. 2002;22:1\u20135.", "ArticleIdList": ["PMC6757630", "12006603"]}, {"Citation": "Gabbouj S, et al. Altered insulin signaling in Alzheimer\u2019s disease brain: Special emphasis on PI3K-Akt pathway. Front. Neurosci. 2019;13:1\u20138. doi: 10.3389/fnins.2019.00629.", "ArticleIdList": ["10.3389/fnins.2019.00629", "PMC6591470", "31275108"]}, {"Citation": "Liu Y, Liu F, Grundke-iqbal I, Iqbal K, Gong C. Deficient brain insulin signalling pathway in Alzheimer\u2019s disease. J. Pathol. 2011;225:54\u201362. doi: 10.1002/path.2912.", "ArticleIdList": ["10.1002/path.2912", "PMC4484598", "21598254"]}, {"Citation": "Ferreira LSS, Fernandes CS, Vieira MNN, De Felice FG. Insulin resistance in Alzheimer\u2019s disease. Front. Neurosci. 2018;12:1\u201311. doi: 10.3389/fnins.2018.00830.", "ArticleIdList": ["10.3389/fnins.2018.00830", "PMC6277874", "30542257"]}, {"Citation": "Neth BJ, Craft S. Insulin resistance and Alzheimer\u2019s disease: Bioenergetic linkages. Front. Neurosci. 2017;12:1\u201320.", "ArticleIdList": ["PMC5671587", "29163128"]}, {"Citation": "Rad SK, et al. Mechanism involved in insulin resistance via accumulation of \u03b2-amyloid and neurofibrillary tangles: Link between type 2 diabetes and Alzheimer\u2019s disease. Drug. Des. Dev. Ther. 2018;12:3999\u20134021. doi: 10.2147/DDDT.S173970.", "ArticleIdList": ["10.2147/DDDT.S173970", "PMC6255119", "30538427"]}, {"Citation": "Gratuze M, Julien J, Petry FR, Morin F, Planel E. Insulin deprivation induces PP2A inhibition and tau hyperphosphorylation in hTau mice, a model of Alzheimer\u2019s disease-like tau pathology. Sci. Rep. 2017;12:1\u201313.", "ArticleIdList": ["PMC5389355", "28402338"]}, {"Citation": "Perry T, et al. Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. J. Neurosci. Res. 2003;72:603\u2013612. doi: 10.1002/jnr.10611.", "ArticleIdList": ["10.1002/jnr.10611", "12749025"]}, {"Citation": "McClean PL, H\u00f6lscher C. Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer\u2019s disease. Neuropharmacology. 2014;86:241\u2013258. doi: 10.1016/j.neuropharm.2014.07.015.", "ArticleIdList": ["10.1016/j.neuropharm.2014.07.015", "25107586"]}, {"Citation": "Tumminia A, Vinciguerra F, Parisi M, Frittitta L. Type 2 diabetes mellitus and Alzheimer\u2019s disease: Role of insulin signalling and therapeutic implications. Int. J. Mol. Sci. 2018;19:1\u201317. doi: 10.3390/ijms19113306.", "ArticleIdList": ["10.3390/ijms19113306", "PMC6275025", "30355995"]}, {"Citation": "Angelopoulou E, Piperi C. DPP-4 inhibitors: A promising therapeutic approach against Alzheimer\u2019s disease. Ann. Transl. Med. 2018;6:255. doi: 10.21037/atm.2018.04.41.", "ArticleIdList": ["10.21037/atm.2018.04.41", "PMC6046299", "30069457"]}, {"Citation": "Batista AF, et al. The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non-human primate model of Alzheimer\u2019s disease. J. Pathol. 2018;245:85\u2013100. doi: 10.1002/path.5056.", "ArticleIdList": ["10.1002/path.5056", "PMC5947670", "29435980"]}, {"Citation": "Lee H, Kumar P, Fu Q, Rosen KM, Querfurth HW. The insulin/akt signaling pathway is targeted by intracellular beta-amyloid. Mol. Biol. Cell. 2009;20:1533\u20131544. doi: 10.1091/mbc.e08-07-0777.", "ArticleIdList": ["10.1091/mbc.e08-07-0777", "PMC2649265", "19144826"]}, {"Citation": "Magran\u00e9 J, Rosen KM, Smith RC, Walsh K, Gouras GK, Querfurth HW. Intraneuronal beta-amyloid expression downregulates the Akt survival pathway and blunts the stress response. J. Neurosci. 2005;25:10960\u201310969. doi: 10.1523/JNEUROSCI.1723-05.2005.", "ArticleIdList": ["10.1523/JNEUROSCI.1723-05.2005", "PMC6725865", "16306409"]}, {"Citation": "Shieh JC, Huang P, Lin Y. Alzheimer\u2019s disease and diabetes: Insulin signaling as the bridge linking two pathologies. Mol. Neurobiol. 2020;57:1966\u20131977. doi: 10.1007/s12035-019-01858-5.", "ArticleIdList": ["10.1007/s12035-019-01858-5", "31900863"]}, {"Citation": "Qu Z-S, et al. Glycogen synthase kinase-3 regulates production of amyloid-\u03b2 peptides and tau phosphorylation in diabetic rat brain. Sci. World J. 2014;2014:1\u20138.", "ArticleIdList": ["PMC3997149", "24983010"]}, {"Citation": "Ly PTT, et al. Inhibition of GSK3\u03b2-mediated BACE1 expression reduces Alzheimer-associated phenotypes find the latest version: Inhibition of GSK3 \u03b2-mediated BACE1 expression reduces Alzheimer-associated phenotypes. J. Clin. Invest. 2013;123:224\u2013235. doi: 10.1172/JCI64516.", "ArticleIdList": ["10.1172/JCI64516", "PMC3533290", "23202730"]}, {"Citation": "Llorens-Mar\u00edtin M, Jurado J, Hern\u00e1ndez F, \u00c1vila J. GSK-3 \u03b2, a pivotal kinase in Alzheimer disease. Front. Mol. Neurosci. 2014;7:1\u201311.", "ArticleIdList": ["PMC4033045", "24904272"]}, {"Citation": "McClean PL, Parthsarathy V, Faivre E, H\u00f6lscher C. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer\u2019s disease. J. Neurosci. 2011;31:6587\u20136594. doi: 10.1523/JNEUROSCI.0529-11.2011.", "ArticleIdList": ["10.1523/JNEUROSCI.0529-11.2011", "PMC6622662", "21525299"]}, {"Citation": "He D, et al. Effects of harmine, an acetylcholinesterase inhibitor, on spatial learning and memory of APP/PS1 transgenic mice and scopolamine-induced memory impairment mice. Eur. J. Pharmacol. 2015;5:96\u2013107. doi: 10.1016/j.ejphar.2015.10.037.", "ArticleIdList": ["10.1016/j.ejphar.2015.10.037", "26526348"]}, {"Citation": "Brunhofer G, et al. Bioorganic & Medicinal Chemistry Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: The case of chelerythrine. Bioorg. Med. Chem. 2012;20:6669\u20136679. doi: 10.1016/j.bmc.2012.09.040.", "ArticleIdList": ["10.1016/j.bmc.2012.09.040", "23062825"]}, {"Citation": "Ryoo S-R, et al. DYRK1A-mediated hyperphosphorylation of Tau A functional link between Down syndrome and Alzheimer disease. J. Biol. Chem. 2007;282:34850\u201334857. doi: 10.1074/jbc.M707358200.", "ArticleIdList": ["10.1074/jbc.M707358200", "17906291"]}, {"Citation": "Frost D, et al. \u03b2-Carboline compounds, including harmine, inhibit DYRK1A and tau phosphorylation at multiple Alzheimer\u2019s disease-related sites. PLoS ONE. 2011;6:e19264. doi: 10.1371/journal.pone.0019264.", "ArticleIdList": ["10.1371/journal.pone.0019264", "PMC3089604", "21573099"]}, {"Citation": "Maynard CJ, Bush AI, Masters CL, Cappai R, Li Q-X. Metals and amyloid-beta in Alzheimer\u2019s disease. Int. J. Exp. Pathol. 2005;86:147\u2013159. doi: 10.1111/j.0959-9673.2005.00434.x.", "ArticleIdList": ["10.1111/j.0959-9673.2005.00434.x", "PMC2517409", "15910549"]}, {"Citation": "Cheignon C, et al. Oxidative stress and the amyloid beta peptide in Alzheimer\u2019s disease. Redox. Biol. 2018;14:450\u2013464. doi: 10.1016/j.redox.2017.10.014.", "ArticleIdList": ["10.1016/j.redox.2017.10.014", "PMC5680523", "29080524"]}, {"Citation": "Manoharan S, et al. The role of reactive oxygen species in the pathogenesis of Alzheimer\u2019s disease, parkinson\u2019s disease, and huntington\u2019s disease: A mini review. Oxid. Med. Cell. Longev. 2016;2016:8590578. doi: 10.1155/2016/8590578.", "ArticleIdList": ["10.1155/2016/8590578", "PMC5223034", "28116038"]}, {"Citation": "Rui D, Yongjian Y. Aluminum chloride induced oxidative damage on cells derived from hippocampus and cortex of ICR mice. Brain Res. 2010;1324:96\u2013102. doi: 10.1016/j.brainres.2010.02.024.", "ArticleIdList": ["10.1016/j.brainres.2010.02.024", "20156420"]}, {"Citation": "Li S-P, et al. Analogous \u03b2-carboline alkaloids harmaline and harmine ameliorate scopolamine-induced cognition dysfunction by attenuating acetylcholinesterase activity, oxidative stress, and inflammation in mice. Front. Pharmacol. 2018;9:346. doi: 10.3389/fphar.2018.00346.", "ArticleIdList": ["10.3389/fphar.2018.00346", "PMC5932362", "29755345"]}, {"Citation": "Osama A, Zhang J, Yao J, Yao X, Fang J. Nrf2: A dark horse in Alzheimer\u2019s disease treatment. Ageing Res. Rev. 2020;64:1\u201346. doi: 10.1016/j.arr.2020.101206.", "ArticleIdList": ["10.1016/j.arr.2020.101206", "33144124"]}, {"Citation": "Steele ML, et al. Effect of Nrf2 activators on release of glutathione, cysteinylglycine and homocysteine by human U373 astroglial cells. Redox Biol. 2013;1:441\u2013445. doi: 10.1016/j.redox.2013.08.006.", "ArticleIdList": ["10.1016/j.redox.2013.08.006", "PMC3814960", "24191238"]}, {"Citation": "Sotolongo K, Ghiso J, Rostagno A. Nrf2 activation through the PI3K/GSK-3 axis protects neuronal cells from A\u03b2-mediated oxidative and metabolic damage. Alzheimer\u2019s Res. Ther. 2020;12:1\u201322. doi: 10.1186/s13195-019-0546-4.", "ArticleIdList": ["10.1186/s13195-019-0546-4", "PMC6958642", "31931869"]}], "ReferenceList": []}], "History": [{"Year": "2021", "Month": "1", "Day": "2"}, {"Year": "2021", "Month": "4", "Day": "22"}, {"Year": "2021", "Month": "6", "Day": "9", "Hour": "6", "Minute": "11"}, {"Year": "2021", "Month": "6", "Day": "10", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "11", "Day": "16", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "6", "Day": "8"}], "PublicationStatus": "epublish", "ArticleIdList": ["34103557", "PMC8187628", "10.1038/s41598-021-90545-4", "10.1038/s41598-021-90545-4"]}}], "PubmedBookArticle": []}